We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ciphergen to Present Data at IGCS

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ciphergen to Present Data at IGCS"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Ciphergen Biosystems, Inc. has announced multiple presentations with its collaborators supporting the use of protein biomarkers to help discriminate women with ovarian cancer from those with benign tumors and to help predict survival in patients with ovarian cancer.

The presentations will be made at the International Gynecologic Cancer Society (IGCS) Biennial Meeting in Santa Monica, Calif., October 14-18.

"A diagnostic test is needed that has adequate predictive value to stratify patients with a pelvic mass into high risk of ovarian cancer from those with low risk," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer for Ciphergen Biosystems.

"As published in the Journal of the National Cancer Institutes in February, studies have shown that women with ovarian cancer have better outcomes when triaged to a gynecologic oncologist for treatment."

"The presentations at IGCS are further evidence supporting the development of Ciphergen's panel of biomarkers to help differentiate women with ovarian cancer and thereby aid in insuring that they receive the most appropriate medical attention."

Each abstract has been presented on Sunday, October 15, 2006 from 12:30-1:30 p.m. during Poster Session 1: Ovarian in the Exhibition Area.

Abstract: A Panel of Seven Biomarkers Improves Detection of Ovarian Cancer
Collaborators: John Hopkins Medical InstitutionsNara Medical University

Abstract: A Panel of Seven Biomarkers Improves Specificity in Discriminating Malignant from Benign Pelvic Masses
Collaborators: The Danish Cancer Society, John Hopkins Medical InstitutionsUniversity of Copenhagen

Abstract: Validation of a Panel of Seven Proteomic Biomarkers in an Independent and Blinded Sample Set
Collaborators: John Hopkins Medical Institutions, Lund University Hospital

Abstract: Novel Biomarkers that Predict Survival in Patients with Ovarian Cancer
Collaborator: University of Copenhagen

Abstract: Evaluation of Pre-Analytic Influence of Sample Collection/Handling Methodologies on Serum Proteome is Key in Biomarker Discovery and Assay Development
Collaborators: University College LondonRoyal Holloway College